Our business strategy focuses on two types of companies: those that have emerged privately from bankruptcy court protection and are owned by their former creditors or those that are privately owned and could benefit from an infusion of equity capital as part of a balance sheet recapitalization. We believe there is a sizable universe of […]

We intend to focus on companies in Technology, Media and Telecommunications (“TMT”) and Information and Communication Technology (“ICT”) industries, specifically the telecommunications infrastructure, internet and technology and digital services sectors operating in Europe and emerging markets (which may include a business based in the U.S., which has operations or opportunities in, Europe and emerging markets […]

(Note: This is NOT an IPO. This is a NASDAQ offering of subordinate voting shares. The company’s stock already trades on the Toronto Stock Exchange. Although Nuvei calls this offering an IPO, it’s NOT a traditional IPO of common stock. IPOScoop has NO CALL on this offering.) We are a global provider of payment technology […]

We are an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles (UTVs), also known as side-by-sides, along with a complete line of upgrades and accessories. In October 2020, we began building and testing prototypes for our future offerings with two off-road motorcycles – the Grunt and […]

We intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare or healthcare-related industries in the United States and Europe. In particular, we intend to prioritize companies in the life sciences sector where our […]

We intend to focus on the space economy, transport and technology industries. Patricia Trompeter, our CEO, has over 20 years of experience in the financial and equity investment industry. She has completed over $17 billion of acquisitions, including transactions in the aircraft leasing industry. She has established a strong network of investment institutions and business connections, […]

We are a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. We develop our product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. […]

We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease […]

We are a clinical stage biopharmaceutical company focused on developing our proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. We plan to develop ABP-450 to address the estimated $2.2 billion global therapeutic botulinum toxin market, which is projected to grow […]

We are a blank check company recently incorporated as a Delaware corporation whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. To date, our efforts have […]